Form 8-K - Current report:
SEC Accession No. 0001193125-25-153429
Filing Date
2025-07-01
Accepted
2025-07-01 07:09:33
Documents
12
Period of Report
2025-07-01
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d940210d8k.htm   iXBRL 8-K 24756
  Complete submission text file 0001193125-25-153429.txt   134757

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA apls-20250701.xsd EX-101.SCH 2850
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20250701_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20250701_pre.xml EX-101.PRE 10812
14 EXTRACTED XBRL INSTANCE DOCUMENT d940210d8k_htm.xml XML 3504
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 251094153
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)